Para a página inicial

Os 122 melhores médicos de imunoterapia do mundo

O conteúdo segue a Política Editorial da Bookimed e foi revisado por

Fahad Mawlood

Mustafa Serkan Alemdar

  • 4.6 Excelente • 7 avaliações
  • 20 anos de experiência
  • Turquia, Antália, Medical Park Antalya Hospital Complex
  • O Dr. Alemdar especializa-se em oncologia médica com formação extensiva na Universidade de Akdeniz – líder em investigação oncológica.

    • Certificado em oncologia médica desde 2018
    • Exerce no complexo hospitalar Medical Park Antalya
    • Mais de _doctor_9570_ anos de experiência em medicina interna e oncologia
    • Formado na Universidade de Akdeniz – o principal centro de investigação oncológica da Turquia
  • Leia mais
Consulta médica
Preço sob consulta
Info

Tarik Salman

  • 32 anos de experiência
  • Turquia, Esmirna, Medicalpoint International Hospital
  • O Dr. Salman especializa-se em imunoterapia para vários tipos de cancro, integrando terapias direcionadas e vacinas contra o cancro. Formou-se em instituições de prestígio como o Memorial Sloan Kettering Cancer Center.

    • Professor associado na Universidade Katip Çelebi com 32 anos de experiência em oncologia médica
    • Investigador visitante no Moffitt Cancer Center na Flórida, EUA
    • Membro do conselho da Sociedade Turca de Oncologia Médica e da Sociedade Europeia de Oncologia Médica
    • Utiliza perfis genómicos abrangentes para planos de tratamento personalizados
    • Ativo em investigação clínica e terapias médicas experimentais
  • Leia mais
Consulta médica
Preço sob consulta
Info

Irfan Cicin

  • 5 Excelente • 1 avaliações
  • 29 anos de experiência
  • Turquia, Istambul, İstinye University Liv Hospital Topkapı
  • Professor de Oncologia Médica com mais de _doctor_10980_ anos de experiência, especializado em tratamentos avançados contra o cancro no Hospital İstinye University Liv Topkapı.

    • Formação especializada em Oncologia Médica na Universidade de Trakya
    • Professor associado e posteriormente professor na Faculdade de Medicina da Universidade de Trakya
    • Membro da Associação Turca de Oncologia Médica
  • Leia mais
Consulta médica
Preço sob consulta
Info

Elkhan Mammadov

  • 4.6 Excelente • 21 avaliações
  • 8 anos de experiência
  • Azerbaijão, Bacu, Liv Bona Dea Hospital Baku
  • O Dr. Elkhan Mammadov é oncologista clínico. Concentra-se no diagnóstico e tratamento do cancro, incluindo quimioterapia citotóxica, hormonoterapia, terapia direcionada (fármacos inteligentes) e imunoterapia.

    Educação: Universidade Médica do Azerbaijão, MD (2004–2010). Universidade de Istambul, Faculdade de Medicina de Istambul, formação em Medicina Interna (2014–2019). Hospital Universitário Istanbul Medipol Mega, formação de subespecialidade em Oncologia Clínica (2019–2022).

    Experiência: 5 anos em Medicina Interna. 3 anos em Oncologia Clínica.

    Afiliações: Sociedade Turca de Oncologia Clínica. ESMO (Sociedade Europeia de Oncologia Clínica). ASCO (Sociedade Americana de Oncologia Clínica).

  • Leia mais
Consulta médica
Preço sob consulta
Info

Li Gui Yuan

  • Novo
  • 23 anos de experiência
  • China, Xangai, Centro de hematologia e terapia celular Shanghai Tongji Hospital
  • Li Guiyuan, MD, is Chief Physician in the Department of Medical Oncology at Shanghai Tongji Hospital. He has practiced oncology since 1996 and has more than 20 years of experience. He earned a master’s degree in Oncology from Nanjing University in 2003. He has worked in the hospital’s Oncology Department since then.

    His clinical work includes chemotherapy for lung, breast, ovarian, and gastrointestinal cancers. He also provides targeted and anti‑angiogenic therapies for malignant tumours. He manages malignant pleural and peritoneal effusions and bone metastases with multimodal care, including immunotherapy.

    He has authored more than 10 basic and clinical papers, including “Tumour Hypoxia and Its Therapeutic Strategies” and “Establishment of Tumour Model with B16 Melanoma Cell Line of C57BL/6 Mice in ICR Mice.” He received the Medical Achievement Award from the General Logistics Department of the PLA for “Research and Application of Early‑diagnosis and Prediction Model for Metastasis of Non‑small‑cell Lung Cancer.” He co‑authored “Evidence‑based Oncology Treatment” and “Handbook of Modern Evidence‑based Diagnosis and Treatment of Cancer.” He has also taken part in key projects of the National Natural Science Foundation of China.

  • Leia mais
Consulta médica
Preço sob consulta
Info

Eytan Aharon Ben-ami

  • 5 Excelente • 2 avaliações
  • 20 anos de experiência
  • Israel, Ramat Gan, Centro Médico Sheba
  • O Dr. Eytan Aharon Ben-Ami lidera a Divisão de Oncologia no Centro Médico Sheba, em Israel. Especializou-se em sarcomas e oncologia óssea no Dana-Farber Cancer Institute. O Dr. Ben-Ami fundou a Organização de Pesquisa Clínica Sheba para promover estudos sobre o câncer. Ele trata tumores ósseos raros e sarcomas de tecidos moles com protocolos personalizados.

    • Chefia a Unidade de Ensaios Clínicos de Fase Inicial para terapias inovadoras contra o câncer.
    • Autor de mais de 40 publicações científicas sobre mecanismos moleculares e detecção precoce.
    • Lidera ensaios de Fase I em terapia direcionada e imunoterapia para cânceres raros.
    • Trabalha no Centro Médico Sheba, um dos 10 melhores hospitais do mundo segundo a Newsweek.
  • Leia mais
Imunoterapia
$2,400 - $3,800
Info

Wolfgang Schröder

  • 25 anos de experiência
  • Alemanha, Wuppertal, Helios Gesundheit
Consulta médica
Preço sob consulta
Info

Francesc Bosch

  • 4.4 Bom • 6 avaliações
  • 126 anos de experiência
  • Espanha, Barcelona, Hospital Quiron Barcelona
  • Líder de renome mundial em leucemia linfocítica crônica (LLC) – o professor Bosch lidera mais de 80 ensaios clínicos sobre novos tratamentos.

    • Especializado em linfomas e LLC com abordagens de tratamento inovadoras
    • Chefe de Hematologia no Instituto de Oncologia IOB
    • Publicou mais de 100 artigos em revistas de alto nível como NEJM e Nature Medicine
    • Professor de Hematologia no Hospital Universitário Vall d'Hebron
  • Leia mais
Consulta médica
Preço sob consulta
Info

Ana Oaknin

  • 4.4 Bom • 6 avaliações
  • 26 anos de experiência
  • acreditações:
  • Espanha, Barcelona, Hospital Quiron Barcelona
  • Investigadora principal em ensaios clínicos focados em imunoterapia para cancros ginecológicos – A Dra. Oaknin lidera pesquisas de vanguarda no Hospital Quiron de Barcelona.

    • Especializada em tratamentos de cancro do ovário, colo do útero e endométrio
    • Autora de mais de 100 publicações e apresentações
    • Membro do conselho executivo do grupo GEICO
    • Membro do corpo docente do Gyn-Track na ESMO
  • Leia mais
Consulta médica
Preço sob consulta
Info

Erkan Gocen

  • 5 Excelente • 1 avaliações
  • 23 anos de experiência
  • Turquia, Tekirdağ, Hospital Optimed International
  • O Dr. Erkan Göcen é especialista em Oncologia Radioterápica no Hospital Privado Çerkezköy Optimed (Optimed Health Group). Formou-se na Universidade de Istambul, Faculdade de Medicina (Çapa), em 2003.

    Carreira: Treinou e praticou em Oncologia Radioterápica de 2010 a 2012. Trabalhou em instituições de saúde públicas e privadas de 2012 a 2016. Trabalhou no setor médico privado como especialista em Oncologia Radioterápica de 2016 a 2023. Está no Hospital Optimed desde 2024.

    Interesses clínicos: cânceres de cérebro, cabeça e pescoço, esôfago, estômago, colorretal, pâncreas, próstata, bexiga, pulmão, tecidos moles (sarcomas), pele, útero e colo do útero, e mama. Afiliações: Sociedade Turca de Oncologia Radioterápica (TROD) e Câmara Médica de Tekirdağ. Idiomas: inglês e turco.

  • Leia mais
Consulta médica
Preço sob consulta
Info

Jesus Soberino

  • 4.4 Bom • 6 avaliações
  • 18 anos de experiência
  • acreditações:
  • Espanha, Barcelona, Hospital Quiron Barcelona
  • Líder em pesquisa de imunoterapia para melanoma e câncer de mama – O Dr. Soberino contribuiu para a aprovação de medicamentos inovadores que revolucionaram o tratamento.

    • Participante chave em ensaios que levaram à aprovação de Pembrolizumab e Nivolumab-Ipilimumab
    • Especializado em superar a resistência à terapia hormonal no câncer de mama
    • Pesquisador ativo em ensaios clínicos de fase 1-3 para novos tratamentos
    • Membro das unidades especializadas de Câncer de Mama e Melanoma de Vall d'Hebron
  • Leia mais
Consulta médica
Preço sob consulta
Info

Francesc Graus

  • 4.4 Bom • 6 avaliações
  • 44 anos de experiência
  • acreditações:
  • Espanha, Barcelona, Hospital Quiron Barcelona
  • O Dr. Graus definiu os primeiros critérios diagnósticos rigorosos para síndromes neurológicas paraneoplásicas – um avanço fundamental na neurotoxicidade relacionada à imunoterapia.

    • 44 anos de especialização em neuro-oncologia e complicações da imunoterapia
    • Identificou anticorpos agora usados mundialmente para diagnosticar distúrbios neurológicos autoimunes
    • Ex-chefe de Neurologia do Hospital Clinic de Barcelona
    • Fundador e ex-presidente da Associação Europeia de Neuro-Oncologia
    • Formação de fellowship no Memorial Sloan-Kettering Cancer Center
  • Leia mais
Consulta médica
Preço sob consulta
Info

Zhang Jinshan

  • 41 anos de experiência
  • 50000+ tratamentos realizados
  • China, Chengdu, uni-asia hospital
  • Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

    1980–1985: Completed doctoral studies at Nagasaki University, Japan

    1968–present: Department of Radiology, Chinese PLA General Hospital

    1988: Third Prize of the Military Science and Technology Progress Award

    1989–present: Member of Radiological Society of North America(RSNA)

    1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

    1991: Second Prize of the Military Science and Technology Progress Award

    1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

    1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

    1993: Granted the Lifetime Special Government Allowance of the State Council

    1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

    1994: Third Prize of the Military Science and Technology Progress Award

    1997: Second Prize of the Military Science and Technology Progress Award

    1997–2009: Standing Member of Chinese Society of Radiology

    1999: Third Prize of the Military Science and Technology Progress Award

    1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

    2002: Second Prize of the Military Science and Technology Progress Award

    2005: Third Prize of the Military Science and Technology Progress Award

    Member of Radiological Society of North America(RSNA)

    Standing Member of Chinese Society of Radiology

    Group Leader of the Group of Intervention of Chinese Journal of Radiology

    Deputy Director Member of Chinese Society of Interventional Oncology

    Director Member of Beijing Medical Association Society of Interventional Radiology

    Deputy Chief Editor of Chinese Journal of Medical Image Technology

    Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

    Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

    Awarded the Special Government Allowance of the State Council

    Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

    Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

    Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

    In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

    zhang-jin-shan

    Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

    zhang-jin-shan

    In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

    zhang-jin-shan

    Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

    zhang-jin-shan

    From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

    Professor Zhang Jinshan’s Academic Achievements

    Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

    Selected Publications by Professor Zhang Jinshan

    1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993,27(6):361-365.

    Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

    2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996,30(8):521-524.

    Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

    3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998,14(3):189-191.

    Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

    4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000,34(5):335-337.

    Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

    5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002,36(7):612-614.

    Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

    6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004,20(9):1395-1397.

    Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

    7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006,40(8):876-878.

    Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

    8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008,28(10):856-858.

    Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

    Professor Zhang Jinshan co-authored monographs

    1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

    2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

    3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

    Professor Zhang Jinshan’s Research project

    1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

    2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

    3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

    4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

  • Leia mais
Info

Nir Kleinmann

  • 5 Excelente • 2 avaliações
  • 25 anos de experiência
  • Israel, Ramat Gan, Centro Médico Sheba
  • O Dr. Nir Kleinmann dirige a Unidade de Endourologia e Cálculos Renais no Sheba Medical Center. Ele é pioneiro em cirurgia a laser de preservação renal para tumores complexos. A Forbes e a ResultMed nomearam-no entre os melhores médicos de Israel para 2025 e 2026. O Dr. Kleinmann utiliza um sistema de laser duplo exclusivo para preservar a função orgânica durante o tratamento do cancro.

    • Completou bolsas de urologia na Universidade Thomas Jefferson e na Universidade McMaster.
    • Especialista em tratamentos minimamente invasivos para UTUC, cálculos renais e cancro da próstata.
    • Atuou como investigador no ensaio OLYMPUS para quimioablação não cirúrgica.
    • Membro da Sociedade Americana de Endourologia com mais de 60 publicações científicas.
  • Leia mais
Imunoterapia
$2,400 - $3,800
Info

Miriam Ben-Harush

  • 5 Excelente • 2 avaliações
  • acreditações:
  • Israel, Haifa, Rambam Medical Center
  • A Prof. Myriam Ben Arush é uma especialista reconhecida internacionalmente em oncologia pediátrica e transplante de medula óssea no Rambam Medical Center.

    • Diretora da Divisão Pediátrica no Hospital Infantil Ruth Rappaport
    • Agraciada com a Legião de Honra na França
    • Nomeada uma das médicas mais dedicadas do mundo pela Associação Médica Mundial
    • Membro do Children's Oncology Group nos EUA
  • Leia mais
Imunoterapia
$3,500 - $9,000
Info

Karen Drumea

  • 5 Excelente • 2 avaliações
  • Israel, Haifa, Rambam Medical Center
  • Especializada em radioterapia e oncologia, a Dra. Karen Drumea traz uma experiência focada em imunoterapia no Rambam Medical Center.

    • Especialista em radioterapia com formação em oncologia
    • Trabalha no Rambam Medical Center
    • Foca na integração da radioterapia com a imunoterapia
  • Leia mais
Imunoterapia
$3,500 - $9,000
Info

Alexander Hauswirth

  • 27 anos de experiência
  • Áustria, Viena, JUVENIS
  • Assoc. Prof. Priv.-Doz. Dr. Alexander W. Hauswirth is a specialist in internal medicine and haemato‑oncology at JUVENIS. Since 2010, he has served as the lead senior physician for Haematology/Haemostaseology and Oncology at the Clinic for Internal Medicine I, Medical University of Vienna/AKH Vienna, Austria’s largest hospital.

    He earned his medical degree from the University of Vienna in 1999. He received the venia docendi in 2010 and was appointed Associate Professor in 2012. He completed an additional haemato‑oncology qualification in 2014. As a Schrödinger Fellow in Salamanca in 2009–2010, he researched CLL stem and precursor cells. He has published regularly since 2000.

    Accreditations include Austrian Medical Chamber diplomas in emergency medicine (since 2009) and sports medicine (2018). Awards include the Schrödinger Fellowship (2009), the ÖGHO award (2009), and the European Society of Chemotherapy poster award (2003). Clinical focus: anaemias, leukaemias, lymph node disorders, clotting and anticoagulation, and pre‑operative clearance. Languages: German and English.

  • Leia mais
Consulta médica
Preço sob consulta
Info

Shute Ailia Dae

  • 5 Excelente • 1 avaliações
  • 13 anos de experiência
  • Turquia, Tekirdağ, Hospital Optimed International
  • Dr. Shute Ailia DAE is a medical oncologist at Optimed International Çorlu Hospital. Dr. Ailia graduated from Dokuz Eylül University Faculty of Medicine in 2013 and completed an internal medicine residency at Bezmialem Vakıf University Hospital in 2018. A hematology–oncology fellowship at Başkent University Hospital followed in 2023.

    From 2018 to 2020, Dr. Ailia served as an internal medicine specialist at Bezmialem Vakıf University Hospital. From 2023 to 2024, Dr. Ailia was an instructor in medical oncology at Başkent University Adana Dr. Turgut Noyan Practice and Research Center.

    Clinical focus includes breast, lung, and prostate cancers. It also covers gastrointestinal cancers (colon, stomach, esophagus, pancreas, liver), lymphomas, melanoma, and gynecologic and genitourinary cancers. Languages: English, Turkish, Swahili.

  • Leia mais
Consulta médica
Preço sob consulta
Info